Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug. Kisunla (donanemab) is the second in a new generation of ...

Eli Lilly has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for Kisunla (donanemab-azbt) ...

“It was a good thing I chose Licca-chan.” Nishimura works at Eli Lilly Japan K.K., a pharmaceutical company in Kobe. Since April 2021, when the company developed a curative drug for alopecia ...